|
[1]
|
Delayed drug hypersensitivity reactions: How p-i transforms pharmacology into immunology
Allergology International,
2025
DOI:10.1016/j.alit.2024.08.006
|
|
|
|
|
[2]
|
Understanding the molecular bridges between the drugs and immune cell
Pharmacology & Therapeutics,
2025
DOI:10.1016/j.pharmthera.2025.108805
|
|
|
|
|
[3]
|
Therapeutic Drug Monitoring
2024
DOI:10.1016/B978-0-443-18649-3.00018-5
|
|
|
|
|
[4]
|
Risk factors for sulfamethoxazole/trimethoprim‐induced severe cutaneous adverse reactions
Clinical & Experimental Allergy,
2024
DOI:10.1111/cea.14470
|
|
|
|
|
[5]
|
Risk factors for sulfamethoxazole/trimethoprim‐induced severe cutaneous adverse reactions
Clinical & Experimental Allergy,
2024
DOI:10.1111/cea.14470
|
|
|
|
|
[6]
|
Genetic associations of human leukocyte antigen alleles in cutaneous delayed drug hypersensitivity reactions: An updated review
Dermatologica Sinica,
2023
DOI:10.4103/ds.DS-D-23-00082
|
|
|
|
|
[7]
|
Drug hypersensitivity and eosinophilia: The decisive role of p‐i stimulation
Allergy,
2023
DOI:10.1111/all.15795
|
|
|
|
|
[8]
|
Genetic associations of human leukocyte antigen alleles in cutaneous delayed drug hypersensitivity reactions: An updated review
Dermatologica Sinica,
2023
DOI:10.4103/ds.DS-D-23-00082
|
|
|
|
|
[9]
|
Advances in understanding of the pathogenesis and therapeutic implications of drug reaction with eosinophilia and systemic symptoms: an updated review
Frontiers in Medicine,
2023
DOI:10.3389/fmed.2023.1187937
|
|
|
|
|
[10]
|
The important role of non‐covalent drug‐protein interactions in drug hypersensitivity reactions
Allergy,
2022
DOI:10.1111/all.14962
|
|
|
|
|
[11]
|
Sulfonamide Hypersensitivity
Clinical Reviews in Allergy & Immunology,
2022
DOI:10.1007/s12016-021-08872-3
|
|
|
|
|
[12]
|
Genetic markers of drug hypersensitivity in pediatrics: current state and promise
Expert Review of Clinical Pharmacology,
2022
DOI:10.1080/17512433.2022.2100345
|
|
|
|
|
[13]
|
Pathology of drug hypersensitivity reactions and mechanisms of immune tolerance
Clinical & Experimental Allergy,
2022
DOI:10.1111/cea.14235
|
|
|
|
|
[14]
|
Pathology of drug hypersensitivity reactions and mechanisms of immune tolerance
Clinical & Experimental Allergy,
2022
DOI:10.1111/cea.14235
|
|
|
|
|
[15]
|
Risk Assessment in Drug Hypersensitivity: Detecting Small Molecules Which Outsmart the Immune System
Frontiers in Allergy,
2022
DOI:10.3389/falgy.2022.827893
|
|
|
|
|
[16]
|
Drug-Induced Severe Cutaneous Adverse Reactions: Insights Into Clinical Presentation, Immunopathogenesis, Diagnostic Methods, Treatment, and Pharmacogenomics
Frontiers in Pharmacology,
2022
DOI:10.3389/fphar.2022.832048
|
|
|
|
|
[17]
|
Genetic markers of drug hypersensitivity in pediatrics: current state and promise
Expert Review of Clinical Pharmacology,
2022
DOI:10.1080/17512433.2022.2100345
|
|
|
|
|
[18]
|
A Comprehensive Review of HLA and Severe Cutaneous Adverse Drug Reactions: Implication for Clinical Pharmacogenomics and Precision Medicine
Pharmaceuticals,
2021
DOI:10.3390/ph14111077
|
|
|
|
|
[19]
|
In-Vitro Approaches to Predict and Study T-Cell Mediated Hypersensitivity to Drugs
Frontiers in Immunology,
2021
DOI:10.3389/fimmu.2021.630530
|
|
|
|
|
[20]
|
Characterization of T-Cell Responses to SMX and SMX-NO in Co-Trimoxazole Hypersensitivity Patients Expressing HLA-B*13:01
Frontiers in Immunology,
2021
DOI:10.3389/fimmu.2021.658593
|
|
|
|
|
[21]
|
A Comprehensive Review of HLA and Severe Cutaneous Adverse Drug Reactions: Implication for Clinical Pharmacogenomics and Precision Medicine
Pharmaceuticals,
2021
DOI:10.3390/ph14111077
|
|
|
|
|
[22]
|
Immune pathomechanism and classification of drug hypersensitivity
Allergy,
2019
DOI:10.1111/all.13765
|
|
|
|
|
[23]
|
Immune pathomechanism and classification of drug hypersensitivity
Allergy,
2019
DOI:10.1111/all.13765
|
|
|
|
|
[24]
|
Multiple Drug Hypersensitivity
International Archives of Allergy and Immunology,
2017
DOI:10.1159/000458725
|
|
|
|
|
[25]
|
T-cell-mediated drug hypersensitivity: immune mechanisms and their clinical relevance
Asia Pacific Allergy,
2016
DOI:10.5415/apallergy.2016.6.2.77
|
|
|
|
|
[26]
|
Classification of Drug Hypersensitivity into Allergic, p-i, and Pseudo-Allergic Forms
International Archives of Allergy and Immunology,
2016
DOI:10.1159/000453265
|
|
|
|
|
[27]
|
Drug Hypersensitivity: How Drugs Stimulate T Cells via Pharmacological Interaction with Immune Receptors
International Archives of Allergy and Immunology,
2015
DOI:10.1159/000441280
|
|
|
|
|
[28]
|
Consequences of drug binding to immune receptors: Immune stimulation following pharmacological interaction with immune receptors (T-cell receptor for antigen or human leukocyte antigen) with altered peptide-human leukocyte antigen or peptide
Dermatologica Sinica,
2013
DOI:10.1016/j.dsi.2013.09.005
|
|
|
|
|
[29]
|
T cell receptor variable β20-1 harbors a nucleotide binding pocket in the CDR2β loop
Open Journal of Immunology,
2013
DOI:10.4236/oji.2013.33021
|
|
|
|